American Association for Cancer Research Annual Meeting

Healio.com brings you the highlights from the American Association for Cancer Research Annual Meeting. Refer back to this page often to read the latest news from AACR, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings.

Ten takeaways from the AACR Annual Meeting

April 24, 2018
This year’s American Association for Cancer Research Annual Meeting featured several potentially practice-changing studies, including many that…
Meeting News

Neoadjuvant pembrolizumab appears effective for resectable melanoma

April 18, 2018
Neoadjuvant pembrolizumab followed by curative-intent resection and adjuvant therapy conferred 1-year recurrence-free survival of 55% among patients…
Meeting News

Biomarkers predict response to pembrolizumab in head and neck squamous cell carcinoma

April 18, 2018
CHICAGO — PD-L1 expression and T-cell activated gene expression profile independently predicted response, PFS and OS among a cohort of patients…
Meeting News

Biomarkers may predict response to nivolumab for urothelial cancer

April 17, 2018
CHICAGO — A combination of PD-L1 expression, circulating myeloid-derived suppressor cells and interferon gamma signatures may identify patients…
Meeting NewsPerspective

Prototype assays may facilitate development of blood tests for early cancer detection

April 17, 2018
CHICAGO — Prototype sequencing assays evaluated in the Circulating Cell-free Genome Atlas study may contribute to the development of a highly…
Meeting NewsPerspective

Calcium channel blockers may increase risk for pancreatic cancer

April 17, 2018
Calcium channel blockers, specifically the short-acting form, appeared associated with increased risk for pancreatic cancer among postmenopausal…
Meeting News

Socioeconomic factors, not race or ethnicity, linked to treatment refusal for advanced lung cancer

April 17, 2018
CHICAGO — Socioeconomic factors influenced whether patients with stage IV non-small cell lung cancer refused cancer treatment, according to…
Meeting NewsPerspective

Pembrolizumab plus CMP-001 demonstrates efficacy for anti-PD-1 resistant melanoma

April 17, 2018
The combination of pembrolizumab and CMP-001, an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with…
Meeting News

Dual IDO1, PD-L1 inhibition safe for advanced solid tumors

April 17, 2018
The addition of the highly selective IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab appeared safe for patients with advanced solid…
Meeting News

Pembrolizumab prolongs survival in recurrent, metastatic head and neck squamous cell carcinoma

April 17, 2018
CHICAGO — Pembrolizumab extended OS compared with standard chemotherapy for patients with relapsed or metastatic head and neck squamous cell…